Trial Profile
Lanreotide In Polycystic Kidney Disease Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Nov 2019
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Acronyms LIPS
- 15 Nov 2019 Status changed from active, no longer recruiting to completed.
- 20 Dec 2017 Planned End Date changed from 1 Apr 2019 to 1 Sep 2019.
- 20 Dec 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Sep 2019.